February 16, 2022

Groundbreaking Drug Treating Nervous System Injuries | NervGen $NGEN $NGENF

Midas Letter
Midas Letter
Groundbreaking Drug Treating Nervous System Injuries | NervGen $NGEN $NGENF

There are no approved drugs that treat nervous system and spinal injuries past stabilizing the patient. There is nothing proved in the clinic to treat injured patients actually recover. NervGen Pharma Corp (CVE:NGEN, OTCMKTS:NGENF) is looking to change that by developing a new class of “neuroreparative” drugs that enable the nervous system to repair itself.

“There’s no approved products that have nervous system repair. So a patient with a spinal cord injury is taken to the hospital, what the doctor will try and do is stabilize the patient and repair the broken bones by surgically stabilizing the spinal cord. After that, it’s really rehab and in some cases, electrostimulation – which helps restore some of their function. But there’s no pharmaceutical therapy right now and patients aren’t really getting over the hump.” – NervGen Pharma CEO Paul Brennan

The company’s lead drug is named NVG-291. The drug is the only one that enables multiple modes of repair: plasticity, regeneration and remyelination. Currently, the drug is a clinical-stage candidate for treating spinal cord injuries, multiple sclerosis and Alzheimer’s disease.

“For an effective product, $50,000 per year, 6 million patients, that’s a $300 billion potential. To put that in perspective, if you were only to take 10% of that, you’d have a $30 billion product and in 2020 the world’s largest pharmaceutical product was HUMIRA at $20 billion. So that would become one of the world’s largest products overnight.” – NervGen Pharma CEO Paul Brennan

NVG-291 is in a phase 1 study conducted on healthy volunteers. The single ascending dose portion has been completed, and the company is now pursuing phase 1b/2 studies in spinal cord injury, Alzheimer’s disease and multiple sclerosis for the drug. The results of these trials will determine how quickly the product will come to market. NervGen is confident its treatment will be publicly available in a much shorter timeframe than most biotech drugs due to the groundbreaking nature of NVG-291.


00:00 – NervGen Pharma $NGEN $NGENF CEO Paul Brennan
00:39 – Business overview
01:04 – Products & clinical trials
01:25 – Total addressable market
02:35 – Pharmaceutical partners
03:18 – Intellectual property (IP)
03:34 – Company story
06:16 – Timeline until treatment availability
07:26 – Economics of business/clinical trials
08:55 – Current approach to treating spinal cord injuries

Related Articles


Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.

Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.

Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.